Table 1.
Activity of Antimicrobial Agents Approved During the Past 5 Years Against Gram-positive Pathogens Causing Skin and Skin Structure Infections
| % of Isolates Susceptible by the Following Criteria: | MIC (µg/mL) | ||||||
|---|---|---|---|---|---|---|---|
| Organism Group and Antimicrobial Agent (Number of Isolates) | Location (Year[s] of Isolation) | CLSI | EUCAST | 50% | 90% | Range | Author (Year) [Reference] |
| Staphylococcus aureus | |||||||
| Dalbavancin; oxacillin-susceptible (27 052) | Global (2002–2007) | – | – | 0.06 | 0.06 | ≤0.03 to 0.25 | Biedenbach et al (2009) [15] |
| Dalbavancin; oxacillin-resistant (19 721) | Global (2002–2007) | – | – | 0.06 | 0.06 | ≤0.03 to 0.5 | Biedenbach et al (2009) [15] |
| Tedizolid (7813) | United States and Europe (2009–2013) | 99.8 | 99.8 | 0.25 | 0.5 | ≤0.015 to 2 | Bensaci & Sahm (2017) [16] |
| Delafloxacin (1350) | United States and Europe (2014) | – | – | ≤0.004 | 0.25 | ≤0.004 to 4 | Pfaller et al (2017) [17] |
| Delafloxacin (903) | Europe and Surrounding Areas (2014–2016) | – | – | ≤0.004 | 0.25 | ≤0.004 to >2 | Huband et al (2017) [18] |
| Delafloxacin (3163) | United States (2014–2016) | – | – | 0.008 | 0.25 | – | Shortridge et al (2017) [19] |
| Delafloxacin (9355) | United States and Europe (2014–2016) | 88.9 | – | 0.008 | 0.5 | – | Flamm et al (2017) [20] |
| MRSA | |||||||
| Tedizolid (3234) | United States and Europe (2009–2013) | 99.6 | 99.6 | 0.25 | 0.5 | ≤0.015 to 2 | Bensaci & Sahm (2017) [16] |
| Oritavancin (not reported) | United States and Europe (2010–2013) | 98.4 (US)/ 98.9 (EU)a | – | 0.03 (US)/ 0.03 (EU) | 0.06 (US)/ 0.06 (EU) | – | Mendes et al (2015) [21] |
| Delafloxacin (573) | United States and Europe (2014) | – | – | 0.06 | 0.5 | ≤0.004 to 4 | Pfaller et al (2017) [17] |
| Delafloxacin (177) | Europe and Surrounding Areas (2014–2016) | – | – | 0.25 | 1 | ≤0.004 to >2 | Huband et al (2017) [18] |
| Delafloxacin (1437) | United States (2014–2016) | – | – | 0.12 | 0.5 | – | Shortridge et al (2017) [19] |
| Delafloxacin (3563) | United States and Europe (2014–2016) | 74.4 | – | 0.12 | 1 | – | Flamm et al (2017) [20] |
| MSSA | |||||||
| Tedizolid (4579) | United States and Europe (2009–2013) | 99.9 | 99.9 | 0.25 | 0.5 | ≤0.015 to 1 | Bensaci & Sahm (2017) [16] |
| Delafloxacin (777) | United States and Europe (2014) | – | – | ≤0.004 | 0.008 | ≤0.004 to 4 | Pfaller et al (2017) [17] |
| Delafloxacin (1726) | United States (2014–2016) | – | – | 0.008 | 0.25 | – | Shortridge et al (2017) [19] |
| Coagulase-negative Staphylococci | |||||||
| Dalbavancin; oxacillin-susceptible (2836) | Global (2002–2007) | – | – | ≤0.03 | 0.06 | ≤0.03 to 1 | Biedenbach et al (2009) [15] |
| Dalbavancin; oxacillin-resistant (9472) | Global (2002–2007) | – | – | ≤0.03 | 0.12 | ≤0.03 to 2 | Biedenbach et al (2009) [15] |
| Tedizolid (623) | United States and Europe (2009–2013) | – | 99.0 | 0.12 | 0.25 | ≤0.008 to 4 | Bensaci & Sahm (2017) [16] |
| Oritavancin (not reported) | United States and Europe (2010–2013) | – (US)/ – (EU)a | – | 0.015 (US)/ 0.03 (EU) | 0.06 (US)/ 0.06 (EU) | – | Mendes et al (2015) [21] |
| Delafloxacin (165) | Europe and Surrounding Areas (2014–2016) | – | – | 0.15 | 0.5 | ≤0.004 to >2 | Huband et al (2017) [18] |
| Delafloxacin (228) | United States (2014–2016) | – | – | 0.015 | 0.5 | – | Shortridge et al (2017) [19] |
| Delafloxacin (1575) | United States and Europe (2014–2016) | – | – | 0.015 | 0.5 | – | Flamm et al (2017) [20] |
| β-hemolytic streptococci | |||||||
| Tedizolid (70) | United States and Europe (2009–2013) | – | 100.0 | 0.12 | 0.25 | ≤0.008 to 0.25 | Bensaci & Sahm (2017) [16] |
| Dalbavancin (5316) | Global (2002–2007) | – | – | ≤0.03 | ≤0.03 | ≤0.03 to 0.25 | Biedenbach et al (2009) [15] |
| Viridans Group Streptococci | |||||||
| Dalbavancin (2148) | Global (2002–2007) | – | – | ≤0.03 | ≤0.03 | ≤0.03 to 0.12 | Biedenbach et al (2009) [15] |
| Tedizolid (51) | United States and Europe (2009–2013) | – | – | 0.12 | 0.25 | ≤0.015 to 0.25 | Bensaci & Sahm (2017) [16] |
| Delafloxacin (294) | United States and Europe (2014) | – | – | 0.015 | 0.03 | ≤0.004 to 2 | Pfaller et al (2017) [17] |
| Streptococcus pyogenes | |||||||
| Tedizolid (684) | United States and Europe (2009–2013) | 100.0 | 100.0 | 0.12 | 0.25 | ≤0.015 to 0.25 | Bensaci & Sahm (2017) [16] |
| Oritavancin (not reported) | United States and Europe (2010–2013) | 98.6 (US)/98.4 (EU)a | – | 0.03 (US)/ 0.03 (EU) | 0.12 (US)/0.12 (EU) | – | Mendes et al (2015) [21] |
| Delafloxacin (433) | United States and Europe (2014) | – | – | 0.008 | 0.015 | ≤0.004 to 0.03 | Pfaller et al (2017) [17] |
| Delafloxacin (1699) | United States and Europe (2014–2016) | >99.9 | – | 0.015 | 0.03 | – | Flamm et al (2017) [20] |
| Streptococcus agalactiae | |||||||
| Tedizolid (715) | United States and Europe (2009–2013) | 100.0 | 100.0 | 0.25 | 0.25 | ≤0.015 to 0.5 | Bensaci & Sahm (2017) [16] |
| Oritavancin (not reported) | United States and Europe (2010–2013) | 97.9 (US)/98.0 (EU)a | – | 0.03 (US)/ 0.03 (EU) | 0.12 (US)/0.12 (EU) | – | Mendes et al (2015) [21] |
| Delafloxacin (225) | United States and Europe (2014) | – | – | 0.008 | 0.015 | ≤0.004 to 0.5 | Pfaller et al (2017) [17] |
| Delafloxacin (827) | United States and Europe (2014–2016) | 98.7 | – | 0.015 | 0.03 | – | Flamm et al (2017) [20] |
| Streptococcus dysgalactiae | |||||||
| Oritavancin (not reported) | United States and Europe (2010–2013) | 100.0 (US)/98.3 (EU)a | – | 0.06 (US)/ 0.06 (EU) | 0.25 (US)/0.5 (EU) | – | Mendes et al (2015) [21] |
| Delafloxacin (132) | United States and Europe (2014) | – | – | 0.008 | 0.015 | ≤0.004 to 0.03 | Pfaller et al (2017) [17] |
| Enterococcus faecalis | |||||||
| Tedizolid (868) | United States and Europe (2009–2013) | 99.4 | – | 0.25 | 0.5 | ≤0.015 to 1 | Bensaci & Sahm (2017) [16] |
| Oritavancin (not reported) | United States and Europe (2010–2013) | 95.6 (US)/ 99.3 (EU)a | – | 0.015 (US)/ 0.015 (EU) | 0.06 (US)/ 0.06 (EU) | – | Mendes et al (2015) [21] |
| Delafloxacin (450) | United States and Europe (2014) | – | – | 0.06 | 1 | ≤0.004 to 2 | Pfaller et al (2017) [17] |
| Delafloxacin (173) | Europe and Surrounding Areas (2014–2016) | – | – | 0.12 | >4 | 0.015 to >4 | Huband et al (2017) [18] |
| Delafloxacin (235) | United States (2014–2016) | – | – | 0.12 | 1 | – | Shortridge et al (2017) [19] |
| Vancomycin-susceptible Enterococcus faecalis | |||||||
| Tedizolid (829) | United States and Europe (2009–2013) | 99.4 | – | 0.25 | 0.5 | ≤0.015 to 1 | Bensaci & Sahm (2017) [16] |
| Enterococcus faecium | |||||||
| Tedizolid (372) | United States and Europe (2009–2013) | – | – | 0.25 | 0.5 | 0.03 to 4 | Bensaci & Sahm (2017) [16] |
| Delafloxacin (295) | United States and Europe (2014) | – | – | >4 | >4 | 0.008 to >4 | Pfaller et al (2017) [17] |
| Vancomycin-susceptible Enterococcus faecium | |||||||
| Tedizolid (168) | United States and Europe (2009–2013) | – | – | 0.25 | 0.5 | 0.03 to 1 | Bensaci & Sahm (2017) [16] |
| Oritavancin (not reported) | United States and Europe (2010–2013) | – (US)/– (EU)a | – | ≤0.008 (US)/ ≤0.008 (EU) | ≤0.008 (US)/ ≤0.008 (EU) | – | Mendes et al (2015) [21] |
| Vancomycin-resistant Enterococcus faecium | |||||||
| Tedizolid (202) | United States and Europe (2009–2013) | – | – | 0.25 | 0.5 | 0.12 to 4 | Bensaci & Sahm (2017) [16] |
| Oritavancin (not reported) | United States and Europe (2010–2013) | – (US)/– (EU)a | – | 0.06 (US)/ 0.015 (EU) | 0.12 (US)/ 0.06 (EU) | – | Mendes et al (2015) [21] |
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; EU, Europe; MRSA, methicillin-resistant Staphylococcus aureus; MIC, minimum inhibitory concentration; MSSA, methicillin-susceptible Staphylococcus aureus.
aThe interpretive criteria used were those approved by the US Food and Drug Administration.